Imasup (Azathioprine)

Azathioprine is converted to 6‑mercaptopurine, which blocks purine synthesis needed for DNA replication. This inhibition reduces the proliferation of lymphocytes, thereby dampening the immune response that drives transplant rejection and autoimmune inflammation.

The dosage of Imasup is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and therapeutic response. Patients should follow the exact regimen provided by their healthcare professional.

The safety of azathioprine during pregnancy or lactation is not fully established. Clinicians weigh potential benefits against risks, and the drug is generally avoided unless the therapeutic advantage justifies possible fetal exposure. Breastfeeding mothers should consult their physician.

To request Imasup, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Azathioprine offers oral administration and a well‑characterized safety profile compared with biologic agents that require injection or infusion. While some newer agents may provide faster onset, azathioprine remains a cost‑effective option for long‑term maintenance in many transplant and autoimmune settings.

Imasup should be stored below 25 °C in a dry environment, kept in its original packaging to protect from moisture, and away from direct sunlight. No refrigeration is required for this oral formulation.

Imasup is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact timing and frequency are determined by the prescribing clinician and should be adhered to strictly.

Serious risks include severe bone marrow suppression leading to pancytopenia, hepatotoxicity, and an increased susceptibility to infections and certain cancers. Patients should be monitored regularly for blood count changes and liver function abnormalities.

Imasup is contraindicated in patients with known hypersensitivity to azathioprine or its metabolites, those with severe bone marrow failure, active uncontrolled infections, or significant liver disease. Caution is also advised for individuals with deficient TPMT enzyme activity.